ClinConnect ClinConnect Logo
Search / Trial NCT05819879

PENG Block vs Sciatico Femoral Block in the Incidence of Post Amputation Syndroms

Launched by NATIONAL CANCER INSTITUTE, EGYPT · Apr 5, 2023

Trial Information

Current as of June 28, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is looking at two different types of nerve blocks, known as the PENG block and the sciatic femoral block, to see how well they help reduce the occurrence of post-amputation syndromes in patients who are having an above-knee amputation due to cancer. Post-amputation syndrome can cause pain and discomfort after surgery, and this study aims to find out which nerve block is more effective in preventing these issues.

To be eligible for the trial, participants should be between the ages of 20 and 60 and classified as ASA class I or II, meaning they are generally healthy or have mild health issues. The trial is open to all genders, but individuals who refuse to participate, have infections at the injection site, or have certain medical conditions—like bleeding disorders or severe heart problems—cannot take part. If you join the study, you can expect to receive one of the two types of nerve blocks before your surgery and be monitored for any post-surgery complications. This is an important opportunity to help improve pain management for future patients undergoing similar procedures.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • ASA class I and II
  • Age above 20 and less than 60 years.
  • Patients undergoing above knee amputation due to any type of cancer
  • Exclusion Criteria:
  • Patient refusal.
  • Local infection at the puncture site.
  • Coagulopathy.
  • Cognitive disorders.
  • Unstable cardiovascular disease.
  • History of psychiatric disorders.
  • History of drug abuse.
  • Patients allergic to medication used.

About National Cancer Institute, Egypt

The National Cancer Institute, Egypt, is a premier research institution dedicated to advancing cancer prevention, treatment, and care through innovative clinical trials and comprehensive research initiatives. As a leading sponsor of clinical studies, the Institute focuses on understanding cancer biology, improving therapeutic strategies, and enhancing patient outcomes. With a commitment to scientific excellence and collaboration, the National Cancer Institute plays a crucial role in addressing the cancer burden in Egypt and the broader region, fostering partnerships with local and international researchers to drive forward the frontiers of oncology.

Locations

Cairo, , Egypt

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported